美国大麻重新排期将提升Ovation Science的CBD产品获取，有望为患有关节炎的老年人提供医疗保险覆盖。 U.S. cannabis rescheduling boosts Ovation Science’s CBD product access, potentially enabling Medicare coverage for seniors with arthritis.

美国政府对大麻的重新分类为Ovation Science的无THC经皮CBD产品打开了潜在途径，这些产品利用Invisicare®技术实现了82%的CBD生物利用度——远超竞争对手。 The U.S. government’s rescheduling of cannabis has opened potential pathways for Ovation Science’s THC-free, transdermal CBD products, which use its Invisicare® technology to achieve 82% CBD bioavailability—far exceeding competitors. 这一变化可能使得今后能够偿还医疗保险费用,改善患有关节炎等炎症的老年人获得治疗的机会,估计影响到6 800万医疗保险注册者中的35%。 The change may enable future Medicare reimbursement, improving access for seniors with inflammation-related conditions like arthritis, affecting an estimated 35% of the 68 million Medicare enrollees. 该公司看到美国和国际市场的许可证、研究和分销机会扩大,通过现有的州级许可证持有者提出了强劲的需求。 The company sees expanded opportunities for licensing, research, and distribution in the U.S. and international markets, citing strong demand through existing state-level licensees. 虽然FDA没有对产品进行医学声明的评估,但Ovation强调临床性能和商业成功. While the FDA has not evaluated the products for medical claims, Ovation emphasizes clinical performance and commercial success.